Denali Therapeutics Inc. (DNLI) Profit Margins
Over the twelve months to 2026-06-30, Denali Therapeutics Inc. (DNLI) had operating margin -15058.2%, net margin -14191.2%, free cash flow margin -12138.1%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
DNLIDenali Therapeutics Inc.Follow DNLI — free
—
Price chart with a free account
- Market cap
- 2.9B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
| Line | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | -35.9% | -810.0% | 18.7% | -607.8% | -314.2% | -59.5% | — | — | -15058.2% | |
| Net margin | -28.1% | -750.8% | 21.2% | -597.2% | -300.6% | -43.9% | — | — | -14191.2% | |
| FCF margin | 36.2% | -644.0% | 123.1% | -451.9% | -242.1% | -112.2% | — | — | -12138.1% |
USD billions · SEC XBRL
Denali Therapeutics Inc. — questions
- What is Denali Therapeutics Inc.'s operating margin?
- -15058.2% over the twelve months to 2026-06-30.
- What is Denali Therapeutics Inc.'s net profit margin?
- -14191.2% over the twelve months to 2026-06-30.
Every figure on this page comes from Denali Therapeutics Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.